# Javier Cortés

Source: https://onco.cc/people/javier-cortes/  
OnCo record `javier-cortes` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breast oncologist who led DESTINY-Breast03 and DESTINY-Breast09, the trials that made Enhertu the HER2-positive standard.

## Summary

Javier Cortés is Head of the International Breast Cancer Center (IBCC) in Barcelona, having built his career at Vall d'Hebron University Hospital and VHIO. His specialisms are breast cancer, HER2-positive disease and antibody-drug conjugates. He was principal investigator of DESTINY-Breast03, which compared trastuzumab deruxtecan with trastuzumab emtansine and was reported in the New England Journal of Medicine, and of DESTINY-Breast09, which tested trastuzumab deruxtecan plus pertuzumab in the first line. He also co-led CLEOPATRA and PHERGain. These trials made trastuzumab deruxtecan the HER2-positive standard, and his publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Head, International Breast Cancer Center (IBCC), Barcelona; formerly Vall d'Hebron
- Specialisms: Breast cancer; HER2-positive disease; Antibody-drug conjugates

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Cortes%20J%5BAuthor%5D%20trastuzumab%20deruxtecan

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- institutions: [Vall d'Hebron University Hospital / VHIO](https://onco.cc/institutions/vall-dhebron/)
- trials: [CLEOPATRA](https://onco.cc/trials/cleopatra/), [DESTINY-Breast03](https://onco.cc/trials/destiny-breast03/), [DESTINY-Breast09](https://onco.cc/trials/destiny-breast09/), [PHERGain](https://onco.cc/trials/phergain/)
- key papers: [ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-ascent-nejm-2021/), [Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial](https://onco.cc/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/), [Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial](https://onco.cc/key-papers/paper-tropion-breast02-ann-oncol-2026/), [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/), [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://onco.cc/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/), [KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-522-nejm-2022/), [monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-monarche-jco-2020/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/javier-cortes.json